Palatin Technologies Implements 1-for-50 Reverse Stock Split to Enhance Share Value

Palatin Technologies Implements 1-for-50 Reverse Stock Split

Palatin Technologies, Inc. (OTCQB: PTNT) has made a pivotal move to improve its financial performance through a reverse stock split at a ratio of 1-for-50, effective as of August 8, 2025. This strategic decision was made to address concerns related to the selling price of its common stock and to satisfy NYSE American’s Listing Qualifications.

Key Details of the Reverse Stock Split

The reverse stock split will see every 50 shares of Palatin’s existing common stock being consolidated into a single share. The adjusted shares will commence trading on the OTCQB Market starting August 11, 2025. The company’s ticker symbol during this transition period will change to PTNTD for a period of 20 trading days, including the effective date of the split.

This administrative action was not taken lightly; it followed approval from stockholders during their annual meeting on July 25, 2025, where they consented to the amendment of the Company's Certificate of Incorporation.

Purpose Behind the Split

The primary objective behind the reverse stock split is to bolster the per-share market price of Palatin's common stock. By doing so, the firm aspires to meet regulatory compliance requirements, thereby securing its position in the market. This is a crucial step for the company, especially if it hopes to attract more significant investments and avoid the risks associated with being listed on a lower-tier market.

Additionally, any fractional shares resulting from this consolidation will be compensated in cash to the shareholders. Importantly, the par value and other specifications surrounding the common stock will remain unchanged, ensuring continuity for existing shareholders.

About Palatin Technologies

Palatin Technologies is a prominent biopharmaceutical company known for developing innovative medicines aimed at treating diseases with substantial unmet medical needs. Its focus is on first-in-class medicines that leverage molecules modifying melanocortin receptor systems. Their targeted product candidates hold great promise for evaluating in clinical settings.

The company’s strategy revolves around advancing its unique melanocortin agonists in partnership with leading pharmaceutical companies, thereby enhancing developmental timelines and maximizing commercial potential.

For further information and updates, stakeholders can access more details through Palatin's official website or follow them on social media platforms.

Conclusion

Overall, Palatin Technologies' decision to undertake a 1-for-50 reverse stock split underlines its commitment to enhancing shareholders’ value while prioritizing compliance with stock exchange requirements. As the pharmaceutical landscape continues to evolve, such strategic financial maneuvers may prove essential in fortifying the company’s future growth and prosperity.